Journal of the Formosan Medical Association
Volume 109, Issue 5 , Pages 338-344 , May 2010

Pemetrexed for Heavily Pretreated Patients With Advanced Non-small Cell Lung Cancer

  • Jih-Hsiang Lee

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Chong-Jen Yu

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Kuan-Yu Chen

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Jin-Yuan Shih

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yu-Lin Lin

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Chih-Hsin Yang

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan
    • Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Chih-Hsin Yang, Department of Oncology, National Taiwan University Hospital, 7 Zhongshan South Road, Taipei, Taiwan

Received 9 April 2009 ,Revised 19 July 2009 ,Accepted 10 August 2009.

References 

  1. Parkin DM , Bray F , Ferlay J , et al.   Global cancer statistics, 2002 . CA Cancer J Clin . 2005;55:74–108
  2. Ramalingam S , Sandler AB . Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection . Oncologist . 2006;11:655–665
  3. Ettinger DS , Bepler G , Bueno R , et al.   Non-small cell lung cancer clinical practice guidelines in oncology . J Natl Compr Canc Netw . 2006;4:548–582
  4. Shepherd FA , Dancey J , Ramlau R , et al.   Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy . J Clin Oncol . 2000;18:2095–2103
  5. Fossella FV , DeVore R , Kerr RN , et al.   Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group . J Clin Oncol . 2000;18:2354–2362
  6. Hanna N , Shepherd FA , Fossella FV , et al.   Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy . J Clin Oncol . 2004;22:1589–1597
  7. Mok T , Wu Y , Thongprasert S , et al.   Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma . N Engl J Med . 2009;361:947–957
  8. Shepherd FA , Rodrigues Pereira J , Ciuleanu T , et al.   Erlotinib in previously treated non-small-cell lung cancer . N Engl J Med . 2005;353:123–132
  9. de Marinis F , Grossi F . Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer . Oncologist . 2008;13(Suppl 1):14–20
  10. Shih C , Chen VJ , Gossett LS , et al.   LY231514, a pyrrolo-[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes . Cancer Res . 1997;57:1116–1123
  11. Scagliotti GV , Ceppi P , Capelletto E , et al.   Updated clinical information on multitargeted antifolates in lung cancer . Clin Lung Cancer . 2009;10(Suppl 1):S35–S40
  12. Belani CP , Brodowicz T , Ciuleanu T , et al.   Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC) . J Clin Oncol . 2009;27:CRA8000; (Meeting Abstracts)
  13. Scagliotti GV , Parikh P , von Pawel J , et al.   Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer . J Clin Oncol . 2008;26:3543–3551
  14. Gronberg BH , Bremnes RM , Flotten O , et al.   Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer . J Clin Oncol . 2009;27:3217–3224
  15. Thatcher N , Chang A , Parikh P , et al.   Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) . Lancet . 2005;366:1527–1537
  16. Ozdogan M , Samur M , Bozcuk H , et al.   Is the thrid-line chemotherapy feasible for non-small cell lung cancer? A retrospective study . Turk J Cancer . 2004;34:19–23
  17. Massarelli E , Andre F , Liu DD , et al.   A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer . Lung Cancer . 2003;39:55–61
  18. Weiss GJ , Langer C , Rosell R , et al.   Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer . J Clin Oncol . 2006;24:4405–4411
  19. Sun JM , Lee KW , Kim JH , et al.   Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer . Jpn J Clin Oncol . 2009;39:27–32
  20. Cullen MH , Zatloukal P , Sorenson S , et al.   A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer . Ann Oncol . 2008;19:939–945
  21. Ohe Y , Ichinose Y , Nakagawa K , et al.   Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer . Clin Cancer Res . 2008;14:4206–4212
  22. Pirker R , Pereira JR , Szczesna A , et al.   Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial . Lancet . 2009;373:1525–1531
  23. Miles DW , Smith IE , Coleman RE , et al.   A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer . Eur J Cancer . 2001;37:1366–1371
  24. Nakagawa K , Kudoh S , Matsui K , et al.   A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours . Br J Cancer . 2006;95:677–682
  25. Ma CX , Nair S , Thomas S , et al.   Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer . J Clin Oncol . 2005;23:5929–5937

PII: S0929-6646(10)60061-7

doi: 10.1016/S0929-6646(10)60061-7

Journal of the Formosan Medical Association
Volume 109, Issue 5 , Pages 338-344 , May 2010

Article Tools